

I. Amendments to the Specification

At page 3, please amend the paragraph beginning on line 21 as follows:

The Nuclear Myosin I  $\beta$  protein has an amino acid sequence shown in FIG. 1 (GenBank Accession Number AY 007255). This amino acid sequence includes an initiator methionine and a 16 amino acid peptide N-terminal to the initiator methionine. The peptide includes the amino acid sequence MRYS ASAL GSDG VRVT (SED ID NO:2) at the N-terminal end.

(At page 3, please amend the paragraph beginning on line 29 as follows:)

In another embodiment of the present invention, antibodies are directed to the Nuclear Myosin I  $\beta$  protein. Additionally, antibodies directed to the peptide comprising the amino acid sequence MRYS ASAL GSDG VRVT (SED ID NO:2) are produced. The antibodies directed to Nuclear Myosin I  $\beta$  protein or to the 16 amino acid peptide as described herein may also be monoclonal antibodies.

(At page 6, please amend the paragraph beginning on line 12 as follows:)

FIG. 3 lists the 5' region of mouse NMI  $\beta$  cDNA (Panel A) and the organization of the myosin I  $\beta$  gene on chromosome 11 (Panel B); in Panel A, the two ATG codons corresponding to the consensus start site and NMI  $\beta$  start site are underlined; the peptide that overlaps the consensus start site that was obtained by microsequencing (ASALGSDGVRVTMESALTAR) (SEQ ID NO:4) is shown in bold; the previously known mouse myosin I  $\beta$  cDNA and protein sequences are in italics.

(At page 12, please amend the paragraph beginning on line 19 as follows)

A 5' RACE was performed using a Mouse Marathon-Ready adapter ligated embryonic mouse cDNA library (Clontech Laboratories, Palo Alto, CA). A myosin I primer (5'-CAGGAGGTAAGTGAATGTGG-3') (SEQ ID NO:5) that anneals 571 bases downstream from the N-terminal end of the gene was used in combination with an AP-1 (adapter primer 5'-CCATCCTAATACGACTCAC TATAGGGC-3') (SEQ ID NO:6). PCR was performed using the Advantage cDNA Polymerase mix (Clontech Labs, Palo Alto, CA).